Physician profile
David Goss
NPI 1154373033
$5,676.68
in general payments reported to CMS, 2019-2025
32 companies · $87.00 in 2025
The $87.00 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,469 · 2020: $341 · 2021: $821 · 2022: $503 · 2023: $280 · 2024: $176 · 2025: $87.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,206.82 | 2019-2021 | |
| Abbvie INC. | $458.52 | 2019-2025 | |
| Gynesonics, INC. | $281.24 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Medtronic USA, INC. | $193.13 | 2019-2020 | |
| Aspira Women'S Health INC | $186.53 | 2019-2021 | |
| Hologic Sales and Service, LLC | $124.82 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $124.02 | 2021-2023 | |
| Agile Therapeutics, INC. | $108.59 | 2021-2024 | Twirla |
| Organon LLC | $86.22 | 2021-2024 | Nexplanon |
| Coopersurgical, INC. | $85.99 | 2020-2024 | Paragard T 380a |
| Evofem Biosciences, INC. | $78.68 | 2021-2022 | |
| Meditrina | $76.39 | 2020-2024 | |
| Exeltis, USA INC. | $75.03 | 2021-2022 | |
| Therapeuticsmd, INC. | $73.42 | 2019-2022 | |
| Astellas Pharma US INC | $68.03 | 2023-2024 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $61.96 | 2023 | Myrisk |
| Daiichi Sankyo INC. | $50.92 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.83 | 2021-2025 | |
| Novo Nordisk INC | $36.60 | 2025 | Wegovy |
| Pfizer INC. | $34.57 | 2022-2024 | |
| Currax Pharmaceuticals LLC | $29.70 | 2022-2023 | Contrave, Onzetra Xsail |
| Myovant Sciences INC. | $29.58 | 2021-2022 | |
| Exact Sciences Corporation | $27.92 | 2023-2024 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $27.51 | 2021 | |
| Roche Diagnostics Corporation | $19.52 | 2019 | |
| Axonics, INC. | $16.46 | 2021 | |
| Allergan, INC. | $15.66 | 2019 | |
| Medtronic, INC. | $13.93 | 2021 | |
| Lupin INC. | $13.84 | 2020 | |
| Mylan Pharmaceuticals INC. | $12.38 | 2020 | |
| Smith+Nephew, INC. | $11.87 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Goss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.